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month period were determined from a claims database.
Data were analyzed using Pearson correlation coefficients.
RESULTS: Results of the interim analysis in 150 respon-
dents (64 adults, 86 children) indicate that patient-
assessed severity had a stronger correlation with DLQI
(r = 0043, p = 0.0004) and CDLQI (r = 0042, p =
0.0011) than did retrospectively assessed severity (r =
0.39, p = 0.0015 [DLQI); and r = 0.10, P = 0044
[CDLQI)). Among the eight domains reported in the SF-
36, the DLQI showed the strongest correlation with the
mental health domain (r = -0.57, P = 0.0001). Visit
counts were significantly correlated with self-assessed se-
verity for adults (r = 0040) and children (r = 0.32).
CONCLUSIONS: A weaker correlation for QOL and
physician visits was observed with retrospectively as-
sessed severity than with patient-assessed severity. Self-
assessed severity of illness correlated moderately well
with QOL and number of physician encounters.
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Although OSHA regulations require that HBV be made
available to health care workers (HCW), the participa-
tion rate with the HBV policy is low. Previous studies ad-
dress characteristics of non-adhering HCW but do not
use this information to subsequently develop organiza-
tional strategies to increase adherence rates.
OBJECTIVE: Determine the vaccination rates of all high-
risk HCW to a HBV policy and to evaluate the effect of
leadership in improving those rates at a military hospital.
METHODS: 118 HCW at high risk for hepatitis B were
categorized by selected variables. Univariate analysis as-
sessed the significance of differences between HBV status
and the selected variables. A conditional probability
model evaluated the response to HBV policy and subse-
quent organizational leadership actions to improve vacci-
nation rates.
RESULTS: Only 61% and 56% of the military and civil-
ian HCW had initiated the HBV series; however, 100%
of the housekeepers completed the series. If a supervisor
had the HBV, the Odds Ratio that the HCW had the
HBV was 8.3 (95% CI 3.3, 21.1). The military HCW
completion rate was increased with passive then active
leadership to 85% then 100%. The civilian HCW com-
pletion rate was increased to 70% then 93%, with pas-
sive then active leadership actions during a six-month fol-
low-up observation period. Surprisingly, directed education
and worksite availability had no effect on the nursing
group. Leading reasons for civilian nurses initially declin-
ing HBV were pregnancy/nursing (36%), needle phobia
(28%), no knowledge of availability (21%), no time
(7%), and no risk perception (7%).
Abstracts
CONCLUSION: Policy alone will not lead to acceptable
HBV rates among HCW. Acceptable rates are achievable
with both combined passive and active organizational
leadership techniques.
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According to the NHANES III data, a majority of pa-
tients require 20-30% reduction in their LDL-cholesterol
to achieve their NCEP goal. Fluvastatin, a HMG-CoA re-
ductase inhibitor (statin), has been shown to be both safe
and effective in achieving 20-30% reductions in LDL-
cholesterol, and of all the statins, it has the lowest drug
acquisition cost.
OBJECTIVE: The purpose of this model was to assess the
economic impact of using a two-drug formulary that in-
cludes fluvastatin and another statin, versus a one-statin
formulary.
METHODS: In a hypothetical cohort of 10,000 patients,
a two-drug formulary with fluvasta tin as the statin of
choice for mild to moderate LDL-cholesterol reduction
and another agent for those patients requiring additional
reduction was compared with a one-drug formulary of
atorvastatin, pravastatin, or simvastatin. NHANES III
data was utilized to estimate the percentage of patients
requiring <30% or ;330% LDL-cholesterol reduction.
Doses used in this model were the average daily doses re-
quired for adequate LDL reduction as estimated by 1997
IMS data, and costs of drug therapy using a weighted
AWP. The cost savings was estimated by subtracting the
combined drug acquisition costs of the two statins from
the cost of a single statin prescribed for 100% of the pa-
tients. Sensitivity analyses were also performed on key
parameters of the model.
RESULTS: Based on NHANES III estimation, over 70% of
patients would require a <30% LDL-cholesterol reduction.
A two-drug formulary using fluvastatin was shown to pro-
vide more cost savings than a single-drug formulary using
any of the other agents, with annual cost difference ranging
from $1.2 million to $3 million per 10,000 patients.
CONCLUSIONS: Using formulary modeling, managed
care decision-makers can measure the economic impact of
their statin choice. This model demonstrates the economic
benefit of using fluvastatin in formulary management.
